Oncology
ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o...
For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Oncology
ASCO 2026: Powerful evidence for the microbiome in oncology,...
Can the state of someone’s gut microbiome – the balance of good and bad bacteria in their digestive tract – affect their response to cancer immunother
Patients
ASCO 2026: Quality of life, not just quantity, with Dr Harol...
Dr Harold Keer, chief medical officer at Taiho Oncology, goes in-depth about why his company places such an emphasis on oral formulations.
Oncology
ASCO 2026: Takeda’s Innovent deal bears fruit, with Teresa B...
Teresa Bitetti and PK Morrow share some of the highlights from Takeda’s data at the show as well as discussing how it fits into their larger strategy.
Oncology
ASCO 2026: First to first line in HER-2 NSCLC, with Itziar C...
At ASCO 2026, BI Global Head of Oncology Itziar Canamasas spoke with pharmaphorum about the company's ASCO data and broader oncology strategy.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
